Long-term clinical outcomes of imiquimod 5% cream vs diclofenac 3% gel for actinic keratosis on the face or scalp: A pooled analysis of two randomized controlled trials
Journal of the European Academy of Dermatology and Venereology Aug 27, 2019
Gollnick H, et al. - Because imiquimod 5% cream (IMIQ) and diclofenac 3% gel (DIC) are commonly used to treat actinic keratosis (AK), however, their long-term impacts after repeated therapy cycles have never been contrasted, researchers compared IMIQ and DIC in AK treatment with the risk of grade III AK or invasive squamous cell carcinoma (SCC) change after 3 years. Immunocompetent adults with 5–10 noticeable AK lesions on the face/scalp and grade I/II AK were eligible for inclusion. A total of 479 patients (IMIQ 242; DIC 237) were involved in the full analysis set. The results obtained from this pooled analysis of two randomized controlled trials indicate that IMIQ has been superior to DIC in clearing AK lesions and preventing histological change to grade III AK or invasive SCC and recurrence over 3 years. Both treatments have been tolerated well.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries